Evaluation of serum IL-39 levels as a potential risk marker in type 2 diabetic patients: a case-control study
International Journal of Nutrology · 28.07.2026 · 19 (S3)
DOI: 10.54448/ijn26s312 ↗Kurz gefasst
Fall-Kontroll-Studie in der Zeitschrift International Journal of Nutrology, online erschienen am 28.07.2026. Verfasst von Hussein Dhahir Ayyez Al‑fatlawiy und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Type 2 diabetes mellitus (T2DM) is a heterogeneous metabolic disorder characterised by chronic hyperglycaemia resulting from defects in insulin secretion, insulin action, or both, leading to long-term damage of multiple organ systems, including the kidneys, retina, nervous system, heart, and blood vessels. Interleukin-39 (IL-39) is a novel heterodimeric member of the IL-12 cytokine family that may participate in the pathogenesis of human inflammatory disorders. Because T2DM is characterised by chronic low-grade inflammation, IL-39 may be a relevant cytokine whose pathogenic involvement in the disease warrants investigation.
Objective
The present study aimed to evaluate the role of serum interleukin-39 in patients with type 2 diabetes mellitus. Materials and Methods: A case-control study was conducted in which serum IL-39 levels were measured in 45 patients with type 2 diabetes mellitus (T2DM) and 45 age- and sex-matched healthy controls. Biochemical measurements included fasting plasma glucose (FPG), glycosylated haemoglobin (HbA1c), total cholesterol, triglycerides, high-density lipoprotein (HDL), and low-density lipoprotein (LDL), measured using spectrophotometric enzymatic colorimetric methods. Serum IL-39 was quantified using an enzyme-linked immunosorbent assay (ELISA) kit.
Results
The mean serum IL-39 level was significantly higher in patients than in controls (11.21 ± 2.38 ng/mL vs. 7.42 ± 1.76 ng/mL; p < 0.001). Serum IL-39 showed a significant positive correlation with FPG (r = 0.298, P = 0.005), HbA1c (r = 0.499, p < 0.001), and body-mass index, and a significant negative correlation with HDL (r = –0.367, p < 0.001). Receiver-operating-characteristic (ROC) curve analysis of serum IL-39 yielded a cut-off value of 8.975 ng/mL, an area under the curve of 0.904, sensitivity of 0.844, specificity of 0.820, and p < 0.001.
Conclusion
Serum IL-39 levels were significantly elevated in patients with T2DM and correlated positively with markers of glycaemic control. ROC analysis demonstrated excellent diagnostic performance of IL-39 in distinguishing T2DM patients from healthy controls. These findings suggest that IL-39 may serve as a potential novel biomarker for T2DM. Graphical Abstract
Zitieren
APA
Al‑fatlawiy, H. D. A., Madhloom, H. A., Hamza, A. A., & Ali, H. A. (2026). Evaluation of serum IL-39 levels as a potential risk marker in type 2 diabetic patients: a case-control study. International Journal of Nutrology, 19(S3). https://doi.org/10.54448/ijn26s312
Vancouver
Al‑fatlawiy HDA, Madhloom HA, Hamza AA, Ali HA. Evaluation of serum IL-39 levels as a potential risk marker in type 2 diabetic patients: a case-control study. International Journal of Nutrology. 2026;19(S3). doi:10.54448/ijn26s312
BibTeX
@article{Alfatlawiy2026,
author = {Al‑fatlawiy, Hussein Dhahir Ayyez and Madhloom, Hasan Ali and Hamza, Asia Ali and Ali, Hanaa Addai},
title = {Evaluation of serum IL-39 levels as a potential risk marker in type 2 diabetic patients: a case-control study},
journal = {International Journal of Nutrology},
year = {2026},
volume = {19},
number = {S3},
doi = {10.54448/ijn26s312}
}
EUVIMED